Chidamide, Lenalidomide, and Rituximab in Newly Diagnosed Elderly/unFit DE-DLBCL

The requested reference [d6c92e029ceebed1e0edf83205562f3a10e3d056] no longer exists in our database. It has been replaced by the current reference: [400eac5c139c64b9acdf26c3aae47f2728a97be6]

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
To evaluate the efficacy and safety of Chidamide in combination with lenalidomide and rituximab (CR2) as induction therapy, followed by chidamide maintenance in responding patients with newly diagnosed elderly/unfit double-expressor DLBCL.
Epistemonikos ID: 989b7785258563e3c1bf9c200c01656e0e3a476b
First added on: Oct 21, 2026